{"id":"W2121743767","doi":"10.1056/nejmoa1110557","title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2050,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase inhibitor; Placebo; Medicine; Janus kinase; Clinical trial; Janus kinase 2; Internal medicine; Double blind; Oncology; Pathology; Alternative medicine; Bone marrow; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06223975921785737,"score_gpt":0.3486815480787401,"score_spread":0.2864417888608828,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}